TY  - GEN
AU  - Gaudinski,Martin R
AU  - Coates,Emily E
AU  - Houser,Katherine V
AU  - Chen,Grace L
AU  - Yamshchikov,Galina
AU  - Saunders,Jamie G
AU  - Holman,LaSonji A
AU  - Gordon,Ingelise
AU  - Plummer,Sarah
AU  - Hendel,Cynthia S
AU  - Conan-Cibotti,Michelle
AU  - Lorenzo,Margarita Gomez
AU  - Sitar,Sandra
AU  - Carlton,Kevin
AU  - Laurencot,Carolyn
AU  - Bailer,Robert T
AU  - Narpala,Sandeep
AU  - McDermott,Adrian B
AU  - Namboodiri,Aryan M
AU  - Pandey,Janardan P
AU  - Schwartz,Richard M
AU  - Hu,Zonghui
AU  - Koup,Richard A
AU  - Capparelli,Edmund
AU  - Graham,Barney S
AU  - Mascola,John R
AU  - Ledgerwood,Julie E
TI  - Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
SN  - 1549-1676
PY  - 2018///1220
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antibodies, Neutralizing
KW  - immunology
KW  - Antibody Formation
KW  - Broadly Neutralizing Antibodies
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - HIV Antibodies
KW  - Half-Life
KW  - Humans
KW  - Infusions, Intravenous
KW  - Infusions, Subcutaneous
KW  - Male
KW  - Middle Aged
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1371/journal.pmed.1002493
ER  -